March’s two biggest news items were both related to recalls, a sign that patient safety remains a top priority throughout the industry. Our in-person coverage from ACC.23 in New Orleans was also popular this month. The conference was jam-packed with fascinating insights and late-breaking clinical trials, and we aimed to cover it all. What happened on Bourbon Street, however, will be staying on Bourbon Street! As always, thank you for reading. – Michael Walter | Editor

The recall includes approximately 2,300 devices distributed to customers prior to July 24, 2017. There have been 44 complaints about this issue so far.

The recall, announced by the FDA, includes multiple lots of dabigatran etexilate capsules.

As much as TAVR's popularity has grown in recent years, there are still many instances when a heart team may find that surgery offers the best path forward. 

Hundreds of physicians participated in the strike, which included a boycott of all outpatient services. The attacked cardiologist was left with a broken nose and missing teeth.

SCAI and the Association of Black Cardiologists have joined forces to share a simple message: PAD patients would be negatively impacted by new CMS proposals. 

Market and regulatory changes in the cardiovascular space are leading to the exodus of procedures to lower-cost settings. Here are 5 strategies to adapt to the growing trend of OBLs and ASCs.

Paul Sorajja, MD, discusses the late-breaking TRILUMINATE pivotal trial at ACC.23 and how tricuspid TEER performed against the current standard of care using medical therapy.

Cardiology has the second largest number of FDA-cleared AI algorithms, and many of them are for cardiac ultrasound. Echocardiography expert Patricia A. Pellikka, MD, discusses this trend and how AI is helping improve echo.

Diving deeper into the data, researchers noted that 40.8% of the payments were tied to speaker fees. Another 19% were from consulting fees.

Atul Verma, MD, director of cardiology at McGill University Health Centre in Montreal, explained why the late-breaking PULSED-AF trial data on Medtronic’s pulsed-field ablation technology is so important for cardiologists.